Gossamer Bio (NASDAQ:GOSS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate of $(0.18) by 14.13 percent. This is a 40 percent decrease over losses of $(0.15) per share from the same period last year. The company reported quarterly sales of $13.799 million which beat the analyst consensus estimate of $7.522 million by 83.44 percent. This is a 47.13 percent increase over sales of $9.379 million the same period last year.